IOL Chemicals Announces 39th AGM on September 2, 2026, via Video Conference
IOL Chemicals and Pharmaceuticals Limited will hold its 39th Annual General Meeting on September 2, 2026, via Video Conference. The agenda includes adopting FY26 financial statements and re-appointing director Mr. Kushal Kumar Rana. Remuneration for the Cost Auditor for FY27 will also be ratified.
The announcement pertains to a standard corporate procedure (AGM) and does not involve any immediate material financial or operational changes for the company. It is a procedural update for shareholders.
The announcement is a routine corporate event (AGM) and does not contain any new financial performance data or significant strategic changes that would warrant a positive or negative sentiment.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has announced its 39th Annual General Meeting (AGM) will be held on Wednesday, September 2, 2026, at 11:30 a.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with current regulations.
The AGM agenda includes the adoption of the Standalone and Consolidated Audited Financial Statements for the financial year ended March 31, 2026, along with the Reports of the Board of Directors and Auditors. Additionally, the shareholders will vote on the re-appointment of Mr. Kushal Kumar Rana as a Director, who retires by rotation.
The meeting will also seek ratification of the remuneration for the Cost Auditor, M/s Ramanath Iyer & Co., for the financial year ending March 31, 2027, set at ₹2,00,000 plus applicable taxes and reimbursement of out-of-pocket expenses. The company's Integrated Annual Report for FY 2025-26, which includes the AGM Notice, is available on the company's website.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.